Annual EBITDA
-$115.45 M
-$31.09 M-36.86%
December 31, 2023
Summary
- As of February 22, 2025, ACRS annual EBITDA is -$115.45 million, with the most recent change of -$31.09 million (-36.86%) on December 31, 2023.
- During the last 3 years, ACRS annual EBITDA has fallen by -$68.26 million (-144.63%).
- ACRS annual EBITDA is now -2100.74% below its all-time high of -$5.25 million, reached on December 31, 2013.
Performance
ACRS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$9.49 M
+$2.92 M+23.53%
September 30, 2024
Summary
- As of February 22, 2025, ACRS quarterly EBITDA is -$9.49 million, with the most recent change of +$2.92 million (+23.53%) on September 30, 2024.
- Over the past year, ACRS quarterly EBITDA has increased by +$19.87 million (+67.68%).
- ACRS quarterly EBITDA is now -268.76% below its all-time high of -$2.57 million, reached on June 30, 2015.
Performance
ACRS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$61.28 M
+$19.87 M+24.49%
September 30, 2024
Summary
- As of February 22, 2025, ACRS TTM EBITDA is -$61.28 million, with the most recent change of +$19.87 million (+24.49%) on September 30, 2024.
- Over the past year, ACRS TTM EBITDA has increased by +$52.47 million (+46.13%).
- ACRS TTM EBITDA is now -2204.70% below its all-time high of -$2.66 million, reached on September 30, 2014.
Performance
ACRS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ACRS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -36.9% | +67.7% | +46.1% |
| 3 y3 years | -144.6% | +50.6% | -6.5% |
| 5 y5 years | -39.3% | +55.3% | +16.9% |
ACRS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -79.1% | at low | at high | +70.4% | at high | +46.9% |
| 5 y | 5-year | -144.6% | at low | -2.6% | +70.4% | -35.0% | +46.9% |
| alltime | all time | -2100.7% | at low | -268.8% | +70.4% | -2204.7% | +46.9% |
Aclaris Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$9.49 M(-23.5%) | -$61.28 M(-24.5%) |
| Jun 2024 | - | -$12.41 M(-21.9%) | -$81.16 M(-19.5%) |
| Mar 2024 | - | -$15.89 M(-32.4%) | -$100.82 M(-12.7%) |
| Dec 2023 | -$115.45 M(+36.9%) | -$23.49 M(-20.0%) | -$115.45 M(+1.5%) |
| Sep 2023 | - | -$29.36 M(-8.5%) | -$113.75 M(+10.6%) |
| Jun 2023 | - | -$32.08 M(+5.1%) | -$102.87 M(+8.3%) |
| Mar 2023 | - | -$30.52 M(+40.1%) | -$94.98 M(+12.6%) |
| Dec 2022 | -$84.36 M(+30.9%) | -$21.79 M(+17.9%) | -$84.36 M(+1.6%) |
| Sep 2022 | - | -$18.48 M(-23.6%) | -$83.06 M(-0.9%) |
| Jun 2022 | - | -$24.19 M(+21.6%) | -$83.79 M(+15.5%) |
| Mar 2022 | - | -$19.90 M(-2.9%) | -$72.56 M(+12.6%) |
| Dec 2021 | -$64.46 M(+36.6%) | -$20.50 M(+6.7%) | -$64.46 M(+12.1%) |
| Sep 2021 | - | -$19.20 M(+48.2%) | -$57.52 M(+20.9%) |
| Jun 2021 | - | -$12.96 M(+9.8%) | -$47.57 M(+4.8%) |
| Mar 2021 | - | -$11.80 M(-13.0%) | -$45.38 M(-2.9%) |
| Dec 2020 | -$47.20 M(-44.7%) | -$13.56 M(+46.6%) | -$46.75 M(-5.9%) |
| Sep 2020 | - | -$9.25 M(-14.2%) | -$49.69 M(-19.4%) |
| Jun 2020 | - | -$10.78 M(-18.1%) | -$61.67 M(-16.4%) |
| Mar 2020 | - | -$13.16 M(-20.2%) | -$73.76 M(-13.7%) |
| Dec 2019 | -$85.41 M | -$16.50 M(-22.3%) | -$85.42 M(-8.6%) |
| Sep 2019 | - | -$21.23 M(-7.1%) | -$93.51 M(+0.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2019 | - | -$22.86 M(-7.9%) | -$93.23 M(-7.3%) |
| Mar 2019 | - | -$24.82 M(+1.0%) | -$100.53 M(-5.5%) |
| Dec 2018 | -$82.90 M(+56.5%) | -$24.59 M(+17.3%) | -$106.43 M(+19.5%) |
| Sep 2018 | - | -$20.96 M(-30.5%) | -$89.05 M(+2.7%) |
| Jun 2018 | - | -$30.16 M(-1.8%) | -$86.73 M(+22.5%) |
| Mar 2018 | - | -$30.73 M(+326.8%) | -$70.81 M(+33.7%) |
| Dec 2017 | -$52.96 M(+10.0%) | -$7.20 M(-61.4%) | -$52.96 M(-7.2%) |
| Sep 2017 | - | -$18.64 M(+30.9%) | -$57.05 M(+16.0%) |
| Jun 2017 | - | -$14.24 M(+10.6%) | -$49.19 M(+2.7%) |
| Mar 2017 | - | -$12.88 M(+14.1%) | -$47.91 M(-0.5%) |
| Dec 2016 | -$48.15 M(+134.0%) | -$11.29 M(+4.7%) | -$48.15 M(+15.7%) |
| Sep 2016 | - | -$10.78 M(-16.8%) | -$41.63 M(+0.4%) |
| Jun 2016 | - | -$12.96 M(-1.2%) | -$41.46 M(+33.4%) |
| Mar 2016 | - | -$13.12 M(+175.1%) | -$31.07 M(+51.0%) |
| Dec 2015 | -$20.58 M(+141.5%) | -$4.77 M(-55.0%) | -$20.58 M(+11.8%) |
| Sep 2015 | - | -$10.61 M(+312.1%) | -$18.41 M(+76.0%) |
| Jun 2015 | - | -$2.57 M(-2.0%) | -$10.46 M(+32.6%) |
| Mar 2015 | - | -$2.63 M(+1.0%) | -$7.88 M(+49.9%) |
| Dec 2014 | -$8.52 M(+62.4%) | -$2.60 M(-2.3%) | -$5.26 M(+97.7%) |
| Sep 2014 | - | -$2.66 M | -$2.66 M |
| Dec 2013 | -$5.25 M | - | - |
FAQ
- What is Aclaris Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Aclaris Therapeutics?
- What is Aclaris Therapeutics annual EBITDA year-on-year change?
- What is Aclaris Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Aclaris Therapeutics?
- What is Aclaris Therapeutics quarterly EBITDA year-on-year change?
- What is Aclaris Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Aclaris Therapeutics?
- What is Aclaris Therapeutics TTM EBITDA year-on-year change?
What is Aclaris Therapeutics annual EBITDA?
The current annual EBITDA of ACRS is -$115.45 M
What is the all time high annual EBITDA for Aclaris Therapeutics?
Aclaris Therapeutics all-time high annual EBITDA is -$5.25 M
What is Aclaris Therapeutics annual EBITDA year-on-year change?
Over the past year, ACRS annual EBITDA has changed by -$31.09 M (-36.86%)
What is Aclaris Therapeutics quarterly EBITDA?
The current quarterly EBITDA of ACRS is -$9.49 M
What is the all time high quarterly EBITDA for Aclaris Therapeutics?
Aclaris Therapeutics all-time high quarterly EBITDA is -$2.57 M
What is Aclaris Therapeutics quarterly EBITDA year-on-year change?
Over the past year, ACRS quarterly EBITDA has changed by +$19.87 M (+67.68%)
What is Aclaris Therapeutics TTM EBITDA?
The current TTM EBITDA of ACRS is -$61.28 M
What is the all time high TTM EBITDA for Aclaris Therapeutics?
Aclaris Therapeutics all-time high TTM EBITDA is -$2.66 M
What is Aclaris Therapeutics TTM EBITDA year-on-year change?
Over the past year, ACRS TTM EBITDA has changed by +$52.47 M (+46.13%)